MGM-15

MGM-15
Clinical data
Other names	Dihydro-7-hydroxy mitragynine
Drug class	Opioid
ATC code	None;
Identifiers
	IUPAC name methyl (E)-2-[(2S,3S,7aS,12aR,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12,12a,12b-octahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate;
CAS Number	1158901-38-2;
PubChem CID	42629165;
Chemical and physical data
Formula	C23H32N2O5
Molar mass	416.518 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@@H]1CN2CC[C@]3([C@@H]([C@@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=C3C(=CC=C4)OC)O;
	InChI InChI=1S/C23H32N2O5/c1-5-14-12-25-10-9-23(27)20-17(7-6-8-19(20)29-3)24-21(23)18(25)11-15(14)16(13-28-2)22(26)30-4/h6-8,13-15,18,21,24,27H,5,9-12H2,1-4H3/b16-13+/t14-,15+,18+,21-,23+/m1/s1; Key:QXFXDJATKPXTFF-LIMHOZKTSA-N;

MGM-15 also known as dihydro-7-hydroxy mitragynine, DH-7OH-MIT, and DHM is an opioid drug which is a semi-synthetic derivative of 7-hydroxymitragynine, a natural product derived from the Southeast Asian tree kratom. MGM-15 was first reported in 2014. It is the 1,2-dihydro derivative of 7-hydroxymitragynine and shows higher potency as an agonist of the μ-opioid receptor and δ-opioid receptor compared to 7-hydroxymitragynine itself. MGM-15 has been sold as a designer drug since early 2025, initially in the US.^[1]^[2]^[3]^[4]^[5]^[6]